Similar articles

• Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?

  Chau I, Cunningham D. Chau I, et al. N Engl J Med. 2002 Apr 4;346(14):1085-7. doi: 10.1056/NEJM200204043461412. N Engl J Med. 2002. PMID: 11932478 No abstract available.
• Cyclooxygenase-2 and colorectal cancer.

  DuBois RN. DuBois RN. Prog Exp Tumor Res. 2003;37:124-37. doi: 10.1159/000071370. Prog Exp Tumor Res. 2003. PMID: 12795052 Review. No abstract available.
• A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.

  Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. Higuchi T, et al. Clin Cancer Res. 2003 Oct 15;9(13):4756-60. Clin Cancer Res. 2003. PMID: 14581346 Clinical Trial.
• [Cyclooxygenase 2 inhibitors and adenomatous polyposis coli].

  Florent C, Meary N. Florent C, et al. Bull Cancer. 2004 May;91 Spec No:S85-8. Bull Cancer. 2004. PMID: 15239335 Review. French.
• The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.

  Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. Jacoby RF, et al. Cancer Res. 2000 Sep 15;60(18):5040-4. Cancer Res. 2000. PMID: 11016626